When was Biofire Diagnostics founded?

Biofire Diagnostics was founded in 1990 and raised its 1st funding round 22 years after it was founded.

Where is Biofire Diagnostics located?

Biofire Diagnostics is headquartered in Salt Lake City, United States.

How many employees does Biofire Diagnostics have?

As of Aug 31, 2026, the latest employee count at Biofire Diagnostics is 598.

Is Biofire Diagnostics a funded company?

Biofire Diagnostics is a funded company, having raised a total of $84M across 7 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Sep 19, 2012.

How much is Biofire Diagnostics worth?

The last known valuation of Biofire Diagnostics was $***** as of Sep 03, 2013.

When was the latest funding round of Biofire Diagnostics?

Biofire Diagnostics' latest funding was a $***** Series A round on Nov 07, 2022, with participation from 7 investors.

Where does Biofire Diagnostics rank among its competitors?

Biofire Diagnostics ranks 14th amongst 422 active competitors, of which 93 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of Biofire Diagnostics?

Biofire Diagnostics' top competitors include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Among them, Daye secured the most recent funding round in November, 2025.

Biofire Diagnostics - 2026 Company Profile, Team, Funding & Competitors

Biofire Diagnostics is an acquired company based in Salt Lake City (United States), founded in 1990 by Carl Wittwer. It operates as a Provider of molecular diagnostic solutions for the detection of genetic conditions. Biofire Diagnostics has raised $84M in funding from Founders Fund, with last known valuation of $*****. The company has 422 active competitors, including 93 funded and 68 that have exited. Its top competitors include companies like Adaptive Biotechnologies, MeMed and HaystackAnalytics.

Company Details

Provider of molecular diagnostic solutions for the detection of genetic conditions. The company is continuously focused on developing new assays for their proprietary FilmArray System, a multiplex PCR system. The product contains Respiratory panel (RP) tests, Blood Culture Identification (BCID) Panel tests, Gastrointestinal (GI) Panel tests, and Meningitis/Encephalitis (ME) Panel tests.

Website: www.biofiredx.com/
Social

Key Metrics

Founded Year

1990

Location

Salt Lake City, United States

Stage

Acquired

Total Funding

$84M in 7 rounds

Latest Funding Round

Series A, Nov 07, 2022, $*****

Last Known Valuation

$***** as on Sep 03, 2013

Investors

Founders Fund & 9 more

Ranked

14^th among 422 active competitors

Employee Count

598 as on Aug 31, 2026

Similar Companies

Adaptive Biotechnologies & 441 more

Exit Details

Acquired by Institut Merieux (Dec 24, 2021)

View Biofire Diagnostics' full profile

Biofire Diagnostics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Biofire Diagnostics, Inc. CIN: 820439851 , United States, Active	Dec 31, 1999	-	8 (As on Dec 31, 2016)	-

Biofire Diagnostics got acquired by Institut Merieux on Dec 24, 2021 at an acquisition amount of $*****.

Click here to take a look at Biofire Diagnostics's acquisition in detail

Biofire Diagnostics has raised a total funding of $84M over 7 rounds. Its first funding round was on Sep 19, 2012. Its latest funding round was a Series A round on Nov 07, 2022 for $*****. 7 investors participated in its latest round. Biofire Diagnostics has 10 institutional investors.

Here is the list of recent funding rounds of Biofire Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 07, 2022	8309709	Series A	9187252	9063505	3428054	6262773
Mar 01, 2015	7961019	Grant (prize money)	1933611	1985447	8982756	HHS
Aug 01, 2014	7757885	Grant (prize money)	8418306	6824748	8975464	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Biofire Diagnostics's funding rounds and investors

The founders of Biofire Diagnostics is Carl Wittwer.

Here are the details of Biofire Diagnostics' key team members:

Carl Wittwer: Co - Founder & Board Chairman of Biofire Diagnostics.

View details of Biofire Diagnostics's Founder profiles and Board Members

Biofire Diagnostics' employee count trend

Biofire Diagnostics has 598 employees as of Aug 26. Here is Biofire Diagnostics's employee count trend over the years:

Employee count trend for Biofire Diagnostics

Uncover Biofire Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biofire Diagnostics include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Here is the list of Top 10 competitors of Biofire Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	72/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
3rd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 33 others	67/100
4th	Huwel Life 2015, Hyderabad (India), Series A	Molecular diagnostic solutions and products for the healthcare industry	$5.74M	Bartronics, BIRAC & 3 others	59/100
5th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
6th	Mylab 2016, Pune (India), Seed	Developer of diagnostic kits for pathogen detection and viral load monitoring	-	Rising Sun Holdings, Zydus Life & 10 others	57/100
7th	Seegene Technologies 2000, Seoul (South Korea), Public	Provider of advanced molecular diagnostics solutions	-	IMM Investment, Songhyun Investment & 3 others	56/100
8th	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Index Ventures, Salica Investments & 24 others	56/100
9th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Redmile Group & 26 others	56/100
10th	ChromaCode 2012, Carlsbad (United States), Series C	Digital molecular biology analytics for disease management	$95M	Northpond Ventures, New Enterprise Associates ... & 9 others	55/100
14th	Biofire Diagnostics 1990, Salt Lake City (United States), Acquired	Provider of molecular diagnostic solutions for the detection of genetic conditions	$84M	Athyrium Capital Management, 10X Capital & 8 others	54/100